A case of generalized eosinophilic pustular folliculitis: treatment with JAK inhibitor.

Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE

Publication: London : Informa Healthcare
Original Publication: Houndmills, Basingstoke, Hampshire, UK : M. Dunitz and Macmillan Press, [c1989]-

Janus Kinase Inhibitors*/therapeutic use ; Folliculitis*/drug therapy ; Eosinophilia*/drug therapy ; Skin Diseases, Vesiculobullous*/drug therapy; Humans ; Adolescent

Aim: This case study aims to report the efficacy and safety of a Janus kinase (JAK) inhibitor in the treatment of generalized eosinophilic pustular folliculitis (EPF).
Methods: We present a case of a 16-year-old Chinese patient who had been suffering from EPF for two years and had shown no response to both topical and systemic glucocorticoids. The patient was subsequently treated with oral tofacitinib at a dosage of 5mg daily.
Results: Significant remission of eruption and pruritus was observed in the patient upon treatment with tofacitinib. However, a relapse occurred upon dose reduction. Subsequent switch to the highly selective JAK1 inhibitor upadacitinib resulted in complete recovery, with the patient achieving a symptom-free status after six months.
Conclusions: JAK inhibitors show promise as a potential treatment option for EPF patients who do not respond to traditional therapies.

Keywords: Eosinophilic pustular folliculitis; JAK inhibitor; eosinophilic pustular folliculitis with follicular mucinosis; eosinophilic skin diseases

0 (Janus Kinase Inhibitors)

Eosinophilic pustular folliculitis

Date Created: 20240326 Date Completed: 20240328 Latest Revision: 20240328

20240329

10.1080/09546634.2024.2331785

38531388